Apnimed Raises $62.5 Million To Advance Its Obstructive Sleep Apnea (OSA) Medication Into Phase 3 Trials
Apnimed believes there is a market for a new pharmaceutical therapeutic option for OSA, which affects 25 million Americans. Muscles that normally maintain the upper airway open collapse periodically during sleep in these people, resulting in occasional low oxygen levels and long-term morbidity. Although continuous positive air pressure can be useful, many patients do not…
